Skip to content

Menu

LexBlog, Inc. logo
CommunitySub-MenuPublishersChannelsProductsSub-MenuBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAboutContactResourcesSubscribeSupport
Join
Search
Close

FDA Shows that it Means Business in Stopping Stem Cell Clinics that Put Patients at Risk

By Mike Druckman, Randy Prebula, David Horowitz, Robert Church, Lowell Zeta, Suzanne Levy Friedman & Jane Kalinina on May 11, 2018
Email this postTweet this postLike this postShare this post on LinkedIn

On Wednesday, FDA announced that it filed two complaints in federal court seeking injunctions to stop marketing efforts of unapproved stem cell treatments by US Stem Cell Clinic of Sunrise, Florida, and California Stem Cell Treatment Center, alleging the treatments seriously harmed patients. Both lawsuits follow up on prior actions that FDA initiated against these clinics in the past year – a Warning Letter against US Stem Cell Clinic (as we reported here) and a court-ordered seizure of product in the possession of California Stem Cell Treatment Center (as we reported here). FDA Commissioner, Scott Gottlieb, M.D., said that while cell-based regenerative medicine holds significant medical opportunity, “[FDA] cannot allow unproven products that exploit the hope of patients and their loved ones.”  In line with the agency’s commitment to enhanced enforcement, Dr. Gottlieb suggested that further enforcement may be on the horizon, stating, “FDA will continue to take enforcement actions against clinics that abuse the trust of patients and endanger their health…”.

FDA has focused on products that pose potential significant safety concerns, including stromal vascular fraction (SVF) therapies (stem cells derived from body fat and other regenerative cells) which are administered by injection. In these new complaints, FDA seeks an injunction against US Stem Cell Clinic, also naming its Chief Scientific Officer and its co-owner and managing officer, for marketing unapproved stem cell therapies, thereby creating infection risks.  Specifically, the agency alleges that the clinic’s therapies are manufactured through a process that FDA asserts deviate significantly from current Good Manufacturing Practices (cGMP), especially with respect to sterility, and that the clinic delayed an FDA inspection.  This complaint comes after the clinic failed to adequately address FDA’s concerns of an August 2017 warning letter.  The complaint alleges that FDA investigators reviewed numerous adverse events records during the 2017 site inspection, specifically referring to patients who received intravitreal (eye) injections of the unapproved product and suffered detached retinas and total blindness.  The agency alleges that the clinic’s “persistent refusal” to promise any corrections (on the basis that FDA lacks authority to regulate the SVF therapies) constitutes continued non-compliance which the court should restrain.

FDA also seeks an injunction against California Stem Cell Treatment Center, after finding the company lacked necessary FDA approvals and failed to correct cGMP deviations that created sterility risks observed during a 2017 inspection.  The complaint also names the Cell Surgical Network as well as two physicians who control the California Stem Cell Treatment Center and approximately 100 other for-profit affiliates through the network company.  FDA noted that the company was administering an unapproved stem cell product created using a combination of SVF and Vaccinia Virus Vaccine (Live) – a vaccine that is reserved only for people at high risk for smallpox.  FDA had seized five vials of the vaccine that the company intended to use in August 2017, as we summarized here following FDA’s announcement.  The product is marketed on the company’s website and brochures, and in YouTube promotional videos with claims referring to the product as “magical cells in your fat,” “liquid magic,” and for cancer therapies including “brain conditions…[by] injecting cells directly into the brain.” Furthermore, the agency alleges that patients were treated at other affiliates using the same protocols and equipment with SVF products, which may suggest further enforcement on the horizon.

FDA’s latest action further evidences the agency’s commitment to increasing oversight and enforcement in the regenerative medicine space, as first announced in November 2017 (previously discussed here).  Last week, Dr. Gottlieb announced that “additional enforcement actions that target some of the bad actors” should be expected.  After the current actions, Dr. Gottlieb reiterated the agency’s intent to take action in order to send a stronger deterrent message to those who are placing patients at risk and harming them. FDA has also recently highlighted a novel and efficient clinical development model as part of the framework for the development and approval of regenerative medicine products, including novel cellular therapies.

We will continue to monitor and report on FDA’s enforcement against US Stem Cell Clinic, California Stem Cell Treatment Center, and any other stem cell clinics as the agency continues to implement its revised risk-based framework.

Photo of David Horowitz David Horowitz

Partner, Washington, D.C.

David Horowitz brings 25 years of combined experience at the U.S. Department of Health and Human Services (HHS) and the FDA to help clients anticipate and navigate regulatory challenges, and participating in the policy-making process.

As Deputy General Counsel at…

Partner, Washington, D.C.

David Horowitz brings 25 years of combined experience at the U.S. Department of Health and Human Services (HHS) and the FDA to help clients anticipate and navigate regulatory challenges, and participating in the policy-making process.

As Deputy General Counsel at HHS (2010-2017), David oversaw and coordinated legal services in support of FDA, the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and international and emergency preparedness programs. His work focused on FDA regulatory policy and litigation. During his tenure at FDA – which included five years as head of the Office of Compliance for drugs, and three years as Assistant Commissioner for Compliance Policy – David played a leadership role in major initiatives, including the modernization of FDA’s approach to pharmaceutical manufacturing quality and the agency’s efforts to develop and implement a more scientific, risk-based approach to inspection and enforcement.

Over the course of his career at HHS and FDA, David developed substantial knowledge pertaining to FDA law and policy, with particular emphasis on pharmaceuticals, compliance, and the application of administrative law. He also developed a deep understanding of the institutions, organizational structures, procedures, and cultures through which regulatory policy and compliance decisions are considered, developed, and implemented across all branches of government, including Congress and the courts, as well as various components of FDA, HHS, Office of Management and Budget, Department of Justice, and the White House.

Read more about David HorowitzEmail
Show more Show less
  • Posted in:
    Administrative
  • Blog:
    Focus on Regulation
  • Organization:
    Hogan Lovells
  • Article: View Original Source

LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center

New to the Network

  • Law of The Ledger
  • Antitrust Law Blog
  • Your ERISA Watch
  • Ciric Law Firm Blog
  • Sacramento Property & Poverty
Copyright © 2022, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo